Table 1.
Patient’s characteristics according to the tumor response after concurrent chemotherapy in preoperative rectal cancer patients
| Variable | Downstaging group | Non-downstaging group | p-value |
|---|---|---|---|
| Gender | 0.685 | ||
| Male | 146 (67.9) | 133 (65.5) | |
| Female | 69 (32.1) | 70 (34.5) | |
| Age (yr) | 0.762 | ||
| <60 | 132 (61.4) | 121 (59.6) | |
| ≥60 | 83 (38.6) | 82 (40.4) | |
| Distance from anal verge (cm) | 0.686 | ||
| <4 | 72 (33.5) | 64 (31.5) | |
| ≥4 | 143 (66.5) | 139 (68.5) | |
| TNM stage | 0.602 | ||
| I | 15 (7.0) | 11 (5.4) | |
| II | 58 (27.0) | 49 (24.1) | |
| III | 142 (66.0) | 143 (70.4) | |
| cT | 0.001* | ||
| cT1 | 2 (0.9) | 2 (1.0) | |
| cT2 | 18 (8.4) | 14 (6.9) | |
| cT3 | 163 (75.8) | 179 (88.2) | |
| cT4 | 32 (14.9) | 8 (3.9) | |
| cN | 0.308 | ||
| cN0 | 75 (34.9) | 61 (30.0) | |
| cN+ | 140 (65.1) | 142 (70.0) | |
| Histological grade | 0.002* | ||
| Low | 202 (94.0) | 172 (84.7) | |
| High | 13 (6.0) | 31 (15.3) | |
| Pretreatment tumor size (cm) | 0.262 | ||
| ≤5 | 145 (67.4) | 126 (62.1) | |
| >5 | 70 (32.6) | 77 (37.9) | |
| Circumferential extent (%) | 0.014* | ||
| ≤60 | 103 (47.9) | 72 (35.5) | |
| >60 | 112 (52.1) | 131 (64.5) | |
| Pretreatment CEA level (ng/mL) | 0.035* | ||
| ≤5 | 153 (71.2) | 132 (65.0) | |
| >5 | 44 (20.5) | 62 (30.5) | |
| Unknown | 18 (8.4) | 9 (4.4) | |
| Chemotherapy regimen | 0.368 | ||
| 5-FU | 134 (62.3) | 136 (67.0) | |
| Capecitabine | 81 (37.7) |
Values are presented as number (%).
CEA, carcinoembryonic antigen; FU, fluorouracil.
*
p<0.05.